Kaitlyn D’Onofrio

DocwireNews

A study observed a correlation between patients&rsquo; expectations toward newly induced disease-modifying antirheumatic drug (DMARD) therapies and clinical response among patients with <a href="https://www.docwirenews.com/docwire-pick/smoking-incident-rheumatoid-arthritis/">rheumatoid arthritis (RA)</a>.&ldquo;The psychosocial dimensions of RA have received considerable attention in the past years. It is generally accepted that the psychosocial state impacts parameters such as disease activity and health-related quality of life (HrQoL) at baseline, but also longitudinally,&rdquo; the study authors explained. &ldquo;However, the association of initial illness perception on outcomes such as HrQoL and disease activity has not yet been investigated.&rdquo;The study comprised 100 patients with RA and an upcoming change in DMARD treatment due to non-response or adverse effects. The Beliefs About Medicines Questionnaire (BMQ), the Short Form 36, and self-designed questions about expectations before treatment initiation (T0) were all used to assess patients&rsquo; treatment beliefs and expectations, as well as HrQoL. Disease Activity Score 28 (DAS28)-C-reactive protein (CRP) was calculated at T0 and after four months (T4). Regression analyses after multiple imputation were implemented to characterize the relationship between patients&rsquo; beliefs and expectations and changes in DAS28-CRP (T0 to T4, &Delta;DAS28-CRP).Data analysis comprised 99 patients, of whom 74 were female. The median age was 62 years (interquartile range, 53.5-70 years). Of the 99 patients, 84 patients completed all questionnaires; 64 of these patients were female. Fifty-three patients were started on a biological DMARD, and 46 were started on a conventional synthetic DMARD. There were no differences between patients started on biological versus conventional synthetic DMARDs. Nearly all patients had a history of failed DMARDs. Most patients had previously received methotrexate (62.6%), while 31.3% had received another conventional synthetic DMARD, and 5.1% treated with a biological DMARD, either alone or in combination with a conventional synthetic DMARD. There was one case of newly diagnosed RA.Of 99 patients included, 84 completed the questionnaires. Overall, expectations per the questionnaires and CRP value at T0 accounted for 36% of all variability in treatment response (&Delta;DAS28-CRP).&ldquo;Among these,&rdquo; the researchers noted, &ldquo;the expected improvement rate, with 10.5%, as well as the CRP-value at T0, with 10.6%, had the greatest positive effect whereas the fear of adverse effects, with 11.4%, and the BMQ.concern scale, with 9.0%, had the greatest negative impact on &Delta;DAS28.&rdquo;A limitation of the study is the fact that it relied on self-reported, unverifiable data from the questionnaires. Patients also enrolled voluntarily and were not randomized.The study was published in <a href="https://journals.sagepub.com/doi/10.1177/1759720X211015829">Therapeutic Advances in Musculoskeletal Disease</a>.&ldquo;The integration of patients&rsquo; preferences and their expectations in treatment decisions could significantly increase clinical outcome. Hence, a more detailed analysis of prevailing expectations and factors that influence these expectations could identify valuable leverage points for non-pharmaceutical options to improve outcome,&rdquo; the study authors wrote in their conclusion.

Jordana Jampel

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

Pulmonology

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Latest News

Could Patients’ Expectations Impact Clinical Response to DMARDs in Rheumatoid Arthritis?

Rheumatoid Arthritis

A study observed a correlation between patients’ expectations toward newly induced disease-modifying antirheumatic drug (DMARD) therapies and clinical response among ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe